Journal
TRANSPLANT INFECTIOUS DISEASE
Volume 16, Issue 2, Pages 213-224Publisher
WILEY
DOI: 10.1111/tid.12186
Keywords
solid organ transplant; hematopoietic cell transplant; histoplasmosis; blastomycosis; coccidioidomycosis
Categories
Funding
- CDC Grant [5U01CI000286-05]
- Merck Co., Inc.
- Astellas US, Inc.
- Pfizer, Inc.
- Schering-Plough Research Institute
- Enzon Pharmaceuticals, Inc.
- Merck
- Pfizer
- Astellas
- T2 Biosystems
- Gilead
- Sigma Tau
- Charles River Laboratories
Ask authors/readers for more resources
BackgroundInvasive fungal infections are a major cause of morbidity and mortality among solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients, but few data have been reported on the epidemiology of endemic fungal infections in these populations. MethodsFifteen institutions belonging to the Transplant-Associated Infection Surveillance Network prospectively enrolled SOT and HCT recipients with histoplasmosis, blastomycosis, or coccidioidomycosis occurring between March 2001 and March 2006. ResultsA total of 70 patients (64 SOT recipients and 6 HCT recipients) had infection with an endemic mycosis, including 52 with histoplasmosis, 9 with blastomycosis, and 9 with coccidioidomycosis. The 12-month cumulative incidence rate among SOT recipients for histoplasmosis was 0.102%. Occurrence of infection was bimodal; 28 (40%) infections occurred in the first 6months post transplantation, and 24 (34%) occurred between 2 and 11years post transplantation. Three patients were documented to have acquired infection from the donor organ. Seven SOT recipients with histoplasmosis and 3 with coccidioidomycosis died (16%); no HCT recipient died. ConclusionsThis 5-year multicenter prospective surveillance study found that endemic mycoses occur uncommonly in SOT and HCT recipients, and that the period at risk extends for years after transplantation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available